2018/11/1 – CRI Report

Research Report on China’s Polyvinyl Chloride (PVC) Industry, 2018-2022

admin — Thu, 01 Nov 2018 06:25:21 +0000

Description
Polyvinyl chloride (PVC) is an important synthetic organic material. As one of the five most common synthetic resins, it is widely used in building materials, industrial products, daily necessities, pipes, wires and cables, packaging film, foaming materials, sealing materials, etc.
China is the world’s largest PVC producer and consumer. At the end of 2017, China’s PVC production capacity exceeded 20 million tons/year. In 2017, the production volume of PVC in China was approximately 17.9 million tons, an increase of 7.2% year-on-year.
In 2017, there were more than 60 PVC producers in China, 20 of which had an annual capacity of 400,000 tons or more. Most of them are located in Inner Mongolia, Xinjiang, Shandong and Qinghai. The two largest PVC producers are situated in Xinjiang, namely, Xinjiang Zhongtai Chemical Co., Ltd. (with an annual production capacity of 2.2 million tons) and Xinjiang Tianye Co., Ltd. (with an annual production capacity of 1.2 million tons). In China, PVC is produced in the calcium carbide method or in the ethylene method. The calcium carbide method accounts for over 80% of China’s PVC production capacity. PVC produced in the calcium carbide method is mainly used in the production of low-end pipes because it contains a large amount of vinyl chloride residues. While PVC made from ethylene, containing little vinyl chloride residue, can be used to produce refined high-end PVC products that cannot be produced with PVC made from calcium carbide. PVC made from ethylene and PVC made from calcium carbide can hardly replace each other.
Economically developed regions such as Guangdong and South China are the major consumers of PVC in China. Guangdong accounts for over 20% of the total PVC consumption in China; Fujian, Shanghai, Jiangsu and Zhejiang in East China account for more than 30% of the national total.
The downstream applications of China’s PVC mainly include construction materials, pipes, etc. Among building materials, sections, doors and windows account for about 30% PVC consumption; pipes account for about 30%; and film accounts for nearly 10%.
According to CRI’s market research, China’s PVC industry is still expanding its production capacity in 2018-2019. It is expected that by the end of 2020, China’s annual PVC production capacity will exceed 27 million tons.
China’s PVC industry is playing an increasingly important role in the global PVC industry. China has grown from a net PVC importer into a net PVC exporter. Especially since 2003 when China took anti-dumping actions against PVC imports, PVC made from calcium carbide has been developing rapidly in China. In 2006, China surpassed the U.S. in both the capacity and volume of PVC production, becoming the largest PVC producer in the world. As the Chinese economy develops and the urbanization rate increases, the demand for PVC will continue to expand in China from 2018 to 2022.

Topics Covered:
– Supply of and demand for PVC in China
– Major PVC producers in China
– Market price of PVC in China
– Competition on China’s PVC market
– Import of PVC in China
– Major driving forces and market opportunities for China’s PVC industry
– Prospect of China’s PVC industry from 2018 to 2022

The post Research Report on China’s Polyvinyl Chloride (PVC) Industry, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Insulin Aspart Market, 2018-2022

admin — Thu, 01 Nov 2018 06:25:17 +0000

Description
The rapid development of the Chinese economy in the past three decades has changed people’s dietary habits and reduced physical activities, which leads to an increasing incidence of obesity-related diseases. It is estimated that at the end of 2017, there were more than 100 million diabetic patients in China. The market size of diabetes drugs is also growing in China.
On Dec. 26, 2001, Novo Nordisk announced that Insulin Aspart (trade name: NovoRapid), the first and only insulin analog that can be used with insulin pumps, was approved by the FDA. Insulin Aspart starts working in 10 to 20 minutes after subcutaneous injection and can reduce postprandial blood glucose and glycated hemoglobin (HbA1c). On the basis of Insulin Aspart, Novo Nordisk developed premixed insulin aspart containing soluble insulin aspart and protaminated insulin aspart of various proportions. The combination of the fast-acting form and the long-acting form allows patients to receive fewer injections over the course of the day. NovoLog Mix 70/30, containing 30% soluble insulin aspart and 70% protaminated insulin aspart, was approved by the FDA in Nov. 2001. Similar NovoLog Mix 50/50 was approved by the FDA in Aug. 2008. In Apr. 2005, NovoMix 30 (30% soluble insulin aspart and 70% protaminated insulin aspart), the first premixed insulin analog, was launched in China. According to CRI, from 2005 to 2017, the sales value of Insulin Aspart in China grew by over 100 times. The market size of Insulin Aspart in China exceeded CNY 200 million in 2017.
Because there are high technical barriers against the imitation of Insulin Aspart, by Oct. 2018, China’s Insulin Aspart market is monopolized by Novo Nordisk’s Insulin Aspart (NovoRapid). According to CRI, several Chinese companies are applying for the CFDA’s approval for generic Insulin Aspart. However, the launch of generic drugs will take several years. With an increasing number of diabetic patients, the market size of Insulin Aspart in China will maintain rapid growth in the next few years.

Topics Covered:
– Situation of diabetes in China
– Sales of Insulin Aspart in China
– Prices of Insulin Aspart in China
– Progress of generic Insulin Aspart in China
– Prospect of China’s Insulin Aspart market from 2018 to 2022

The post Investigation Report on China’s Insulin Aspart Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Acarbose Market, 2018-2022

admin — Thu, 01 Nov 2018 06:25:12 +0000

Description
According to CRI, with improved living standards, ageing population, and increasing obesity rate, the incidence of diabetes has been climbing in China. By the end of 2017, the number of diabetic patients in China exceeded 100 million, ranking first in the world and promoting the development of the diabetes drug market.
Acarbose was developed by Bayer in 1975 and first launched in Switzerland in 1986 (trade name: Glucobay). As the first FDA-approved alpha-glycosidase inhibitor in the world, it entered China in 1994 and is now recommended as a first-line drug for type 2 diabetes. Acarbose is sold far better in China than in developed countries because it reduces glucose uptake mainly by inhibiting amylase and is more suitable for Asians who eat mainly carbohydrates.
Although Acarbose has been marketed in China for more than 20 years, China’s Acarbose market is dominated by Bayer, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. and Sichuan Luye Baoguang Pharmaceutical Co., Ltd. because it is difficult to imitate Acarbose. In recent years, the market share of Bayer’s Acarbose (trade name: Glucobay) is declining in China year by year, while the market share of domestic-made counterparts is rising. In 2017, the market size of Acarbose in China was about CNY 1.09 billion. Bayer’s market share was about 66.4%, showing a continued momentum of decline.
According to CRI, from 2018 to 2022, the market size will continue to grow as the number of diabetic patients increases.

Topics Covered:
– Development environment of Acarbose in China
– Supply of and demand for Acarbose in China
– Competition on China’s Acarbose market
– Prices of Acarbose in China
– Forecasts on China’s Acarbose market from 2018 to 2022

The post Investigation Report on China’s Acarbose Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China Entecavir 2018-2022

admin — Thu, 01 Nov 2018 06:25:06 +0000

Description
The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China, among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese is estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.
Entecavir, an oral drug of oral deoxyguanosine, was developed by Bristol-Myers Squibb and approved to enter the market by FDA in Mar. 2005. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd got CFDA’s approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent. According to CRI’s market survey, the annual sales value of entecavir in China rose from CNY1126.04 million in 2013 to CNY 1995.69 million in 2017 and CAGR during this period reached up to 15.38%. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 39.82% in 2017 for sales value and 23.96% for sales volume.
Compared with the original nucleoside analogue, entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance. Entecavir makes it possible for patients to start with monotherapy which could be successful over a long term. As is known to all, new drug’s entering into the anti-HBV drug market is bound to pose a threat to old ones, forming a new competitive landscape. Due to the lack of new antiviral drugs for Hepatitis B in a long time, the market demand is far from being satisfied. Therefore, entecavir is estimated to enjoy good market prospects and its sales value will keep growing in the next few years.

Topics covered
-market size of entecavir in China
-competitive landscape of entecavir in Chinese market
-price of entecavir made by different manufacturers in China
-market outlook of entecavir in China

The post Investigation Report on China Entecavir 2018-2022 first appeared on CRI Report.